Overview

Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Idera Pharmaceuticals, Inc.